Impact of Obeticholic Acid on the Lipoprotein Profile in Patients with Nonalcoholic Steatohepatitis

BACKGROUND: Farnesoid X receptor (FXR) agonist, obeticholic acid (OCA), increases total and low-density lipoprotein cholesterol (LDL-C) in patients with nonalcoholic steatohepatitis (NASH). The present study evaluated the impact of OCA therapy on lipoprotein sub-particles. METHOD: The study included...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Hepatol
Autori principali: Siddiqui, Mohammad Shadab, Van Natta, Mark L., Connelly, Margery A., Vuppalanchi, Raj, Neuschwander-Tetri, Brent A., Tonascia, James, Guy, Cynthia, Loomba, Rohit, Dasarathy, Srinivasan, Wattacheril, Julia, Chalasani, Naga, Sanyal, Arun J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6920569/
https://ncbi.nlm.nih.gov/pubmed/31634532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2019.10.006
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi